What is it?
Endometrial Receptivity Analysis (ERA) is a diagnostic method developed and patented by IGENOMIX R&D department since 2009, after more than 10 years research. It is a genetic test that uses a small sample of the women’s endometrial tissue to evaluate whether or not the endometrial lining is prepared to accept an implanting embryo.
The ERA is performed using a biopsy of the uterus lining. The biopsy is performed during a “mock” FET cycle on the same day that the embryo transfer is normally performed. During the “mock” FET cycle progesterone is administered for four or six days depending on the age of the embryo. Progesterone is a hormone that helps the endometrium become receptive. The biopsy is then timed to be carried out at the end of the progesterone administration . Once the biopsy has been obtained, the genes involved in receptivity are analyzed by the Igenomix Laboratory in Japan and the ERA predicts the endometrium to be “receptive” or “non-receptive” on the day the transfer would have occurred.
Who is it suitable for?
The ERA is suitable for women who experience “recurrent implantation failure”.
Please contact PIVET Medical Centre for further information.
